Open AccessEfficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer
Author(s) -
Yuanyuan Yu,
Zicheng Zhang,
Qianhao Meng,
Ke Wang,
Qingwei Li,
Yue Ma,
Yuanfei Yao,
Jie Sun,
Guangyu Wang
Publication year - 2022
Publication title -
journal of gastric cancer/daehan wiam haghoeji
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.806
H-Index - 28
eISSN - 2093-5641
pISSN - 1598-1320
DOI - 10.5230/jgc.2022.22.e11
Subject(s) - medicine , capecitabine , oxaliplatin , chemotherapy , hazard ratio , stage (stratigraphy) , confidence interval , cancer , gastroenterology , oncology , surgery , colorectal cancer , biology , paleontology
We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received the standard number of cycles of chemotherapy.